Home/Filings/4/0001562180-24-007701
4//SEC Filing

CARREL MICHAEL H 4

Accession 0001562180-24-007701

CIK 0001603756other

Filed

Nov 14, 7:00 PM ET

Accepted

Nov 15, 8:58 AM ET

Size

14.0 KB

Accession

0001562180-24-007701

Insider Transaction Report

Form 4
Period: 2024-11-15
Transactions
  • Disposition to Issuer

    Common Stock

    2024-11-15$71.00/sh17,861$1,268,1310 total
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2024-11-15$36.90/sh5,000$184,5000 total
    Exercise: $34.10Exp: 2029-08-22Common Stock (5,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2024-11-15$50.15/sh10,000$501,5000 total
    Exercise: $20.85Exp: 2029-02-27Common Stock (10,000 underlying)
Footnotes (2)
  • [F1]Reflects the disposition of the reporting person's shares of the Issuer's common stock, upon the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 8, 2024 (the "Merger Agreement"), among the Issuer, Boston Scientific Corporation ("Parent") and Sadie Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger of Merger Sub with and into the Issuer with the Issuer as the surviving corporation (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive $71.00 in cash, without interest (the "Merger Consideration").
  • [F2]Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of the Issuer's common stock granted under the Issuer's 2018 Omnibus Incentive Plan (f/k/a/ Axonics Modulation Technologies, Inc. 2018 Omnibus Incentive Plan) and the Axonics Modulation Technologies, Inc. 2014 Stock Incentive Plan (each such option, a "Company Option"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Company Option and (b) the aggregate number of shares of the Issuer's common stock issuable upon exercise of such Company Option, less applicable taxes and authorized deductions.

Issuer

Axonics, Inc.

CIK 0001603756

Entity typeother

Related Parties

1
  • filerCIK 0001230584

Filing Metadata

Form type
4
Filed
Nov 14, 7:00 PM ET
Accepted
Nov 15, 8:58 AM ET
Size
14.0 KB